Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Clark JI, et al. Among authors: taback b. Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29. Clin Genitourin Cancer. 2017. PMID: 27916626 Free PMC article.
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.
Hasanov M, Milton DR, Sharfman WH, Taback B, Cranmer LD, Daniels GA, Flaherty L, Hallmeyer S, Milhem M, Feun L, Hauke R, Doolittle G, Gregory N, Patel S. Hasanov M, et al. Among authors: taback b. Oncoimmunology. 2021 Oct 9;10(1):1984059. doi: 10.1080/2162402X.2021.1984059. eCollection 2021. Oncoimmunology. 2021. PMID: 34650833 Free PMC article. Clinical Trial.
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
Clark JI, Singh J, Ernstoff MS, Lao CD, Flaherty LE, Logan TF, Curti B, Agarwala SS, Taback B, Cranmer L, Lutzky J, Luna TL, Aung S, Lawson DH. Clark JI, et al. Among authors: taback b. J Immunother Cancer. 2018 Jul 27;6(1):76. doi: 10.1186/s40425-018-0387-x. J Immunother Cancer. 2018. PMID: 30053905 Free PMC article. Clinical Trial.
Cytokine therapy for cancer.
Kim-Schulze S, Taback B, Kaufman HL. Kim-Schulze S, et al. Among authors: taback b. Surg Oncol Clin N Am. 2007 Oct;16(4):793-818, viii. doi: 10.1016/j.soc.2007.07.011. Surg Oncol Clin N Am. 2007. PMID: 18022545 Review.
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S. Kaufman HL, et al. Among authors: taback b. J Transl Med. 2009 Jan 7;7:2. doi: 10.1186/1479-5876-7-2. J Transl Med. 2009. PMID: 19128501 Free PMC article. Clinical Trial.
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O. Hallmeyer S, et al. Among authors: taback b. Melanoma Res. 2017 Dec;27(6):585-590. doi: 10.1097/CMR.0000000000000398. Melanoma Res. 2017. PMID: 29076950 Clinical Trial.
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gérard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst BA, Saenger YM. Gartrell RD, et al. Among authors: taback b. Clin Cancer Res. 2019 Apr 15;25(8):2494-2502. doi: 10.1158/1078-0432.CCR-18-2847. Epub 2019 Jan 15. Clin Cancer Res. 2019. PMID: 30647081 Free PMC article.
85 results